nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—Temsirolimus—kidney cancer	0.126	0.5	CrCtD
Sirolimus—Everolimus—kidney cancer	0.126	0.5	CrCtD
Sirolimus—Protein Kinase Inhibitors—Temsirolimus—kidney cancer	0.0923	0.344	CiPCiCtD
Sirolimus—MTOR—kidney cancer	0.0746	0.853	CbGaD
Sirolimus—Protein Kinase Inhibitors—Sunitinib—kidney cancer	0.0699	0.261	CiPCiCtD
Sirolimus—Protein Kinase Inhibitors—Pazopanib—kidney cancer	0.053	0.198	CiPCiCtD
Sirolimus—Protein Kinase Inhibitors—Everolimus—kidney cancer	0.053	0.198	CiPCiCtD
Sirolimus—MTOR—Everolimus—kidney cancer	0.0426	0.268	CbGbCtD
Sirolimus—FKBP1A—Everolimus—kidney cancer	0.0368	0.231	CbGbCtD
Sirolimus—MTOR—Temsirolimus—kidney cancer	0.0288	0.181	CbGbCtD
Sirolimus—Temsirolimus—Everolimus—kidney cancer	0.0272	0.167	CrCrCtD
Sirolimus—Tacrolimus—Everolimus—kidney cancer	0.0272	0.167	CrCrCtD
Sirolimus—Pimecrolimus—Temsirolimus—kidney cancer	0.0272	0.167	CrCrCtD
Sirolimus—Pimecrolimus—Everolimus—kidney cancer	0.0272	0.167	CrCrCtD
Sirolimus—Everolimus—Temsirolimus—kidney cancer	0.0272	0.167	CrCrCtD
Sirolimus—Tacrolimus—Temsirolimus—kidney cancer	0.0272	0.167	CrCrCtD
Sirolimus—FKBP1A—Temsirolimus—kidney cancer	0.0249	0.156	CbGbCtD
Sirolimus—ABCB1—kidney cancer	0.0128	0.147	CbGaD
Sirolimus—CYP3A7—Temsirolimus—kidney cancer	0.00241	0.0151	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Temsirolimus—kidney cancer	0.00241	0.0151	CbGbCtD
Sirolimus—SLCO1B1—Pazopanib—kidney cancer	0.00216	0.0136	CbGbCtD
Sirolimus—CYP3A5—Temsirolimus—kidney cancer	0.00181	0.0114	CbGbCtD
Sirolimus—ABCB1—Temsirolimus—kidney cancer	0.00118	0.00739	CbGbCtD
Sirolimus—CYP3A4—Everolimus—kidney cancer	0.00104	0.00655	CbGbCtD
Sirolimus—CYP3A7—Paclitaxel—kidney cancer	0.000826	0.00519	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Paclitaxel—kidney cancer	0.000826	0.00519	CbGbCtD
Sirolimus—CYP3A7—Sorafenib—kidney cancer	0.000734	0.00461	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Sorafenib—kidney cancer	0.000734	0.00461	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Vincristine—kidney cancer	0.000712	0.00448	CbGbCtD
Sirolimus—CYP3A7—Vincristine—kidney cancer	0.000712	0.00448	CbGbCtD
Sirolimus—CYP3A4—Temsirolimus—kidney cancer	0.000704	0.00443	CbGbCtD
Sirolimus—CYP3A5—Erlotinib—kidney cancer	0.000677	0.00426	CbGbCtD
Sirolimus—CYP3A5—Paclitaxel—kidney cancer	0.00062	0.0039	CbGbCtD
Sirolimus—ABCB1—Pazopanib—kidney cancer	0.000618	0.00388	CbGbCtD
Sirolimus—EIF4E—Temsirolimus—Everolimus—kidney cancer	0.000612	1	CbGdCrCtD
Sirolimus—CYP3A7—Sunitinib—kidney cancer	0.000595	0.00374	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Sunitinib—kidney cancer	0.000595	0.00374	CbGbCtD
Sirolimus—EIF4E—renal system—kidney cancer	0.00059	0.0991	CbGeAlD
Sirolimus—EIF4E—kidney—kidney cancer	0.00057	0.0958	CbGeAlD
Sirolimus—ABCB1—Dactinomycin—kidney cancer	0.000565	0.00355	CbGbCtD
Sirolimus—CYP3A5—Sorafenib—kidney cancer	0.000551	0.00346	CbGbCtD
Sirolimus—CYP3A5—Vincristine—kidney cancer	0.000534	0.00336	CbGbCtD
Sirolimus—EIF4E—gonad—kidney cancer	0.000529	0.0889	CbGeAlD
Sirolimus—ABCB1—Gemcitabine—kidney cancer	0.000446	0.00281	CbGbCtD
Sirolimus—CYP3A5—Sunitinib—kidney cancer	0.000446	0.0028	CbGbCtD
Sirolimus—ABCB1—Erlotinib—kidney cancer	0.000441	0.00277	CbGbCtD
Sirolimus—ABCB1—Paclitaxel—kidney cancer	0.000403	0.00254	CbGbCtD
Sirolimus—CYP3A4—Pazopanib—kidney cancer	0.00037	0.00233	CbGbCtD
Sirolimus—ABCB1—Sorafenib—kidney cancer	0.000358	0.00225	CbGbCtD
Sirolimus—ABCB1—Vinblastine—kidney cancer	0.000354	0.00222	CbGbCtD
Sirolimus—ABCB1—Vincristine—kidney cancer	0.000348	0.00219	CbGbCtD
Sirolimus—ABCB1—Sunitinib—kidney cancer	0.00029	0.00182	CbGbCtD
Sirolimus—Pimecrolimus—MTOR—kidney cancer	0.000278	0.287	CrCbGaD
Sirolimus—Everolimus—MTOR—kidney cancer	0.000278	0.287	CrCbGaD
Sirolimus—CYP3A4—urine—kidney cancer	0.000274	0.046	CbGeAlD
Sirolimus—CYP3A4—Erlotinib—kidney cancer	0.000264	0.00166	CbGbCtD
Sirolimus—CYP3A4—Paclitaxel—kidney cancer	0.000242	0.00152	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—nephron tubule—kidney cancer	0.000237	0.0399	CbGeAlD
Sirolimus—MTOR—renal system—kidney cancer	0.000228	0.0383	CbGeAlD
Sirolimus—MTOR—kidney—kidney cancer	0.000221	0.0371	CbGeAlD
Sirolimus—ABCB1—Doxorubicin—kidney cancer	0.000217	0.00137	CbGbCtD
Sirolimus—CYP3A4—Sorafenib—kidney cancer	0.000215	0.00135	CbGbCtD
Sirolimus—CYP3A4—Vinblastine—kidney cancer	0.000212	0.00133	CbGbCtD
Sirolimus—CYP3A4—Vincristine—kidney cancer	0.000208	0.00131	CbGbCtD
Sirolimus—FKBP1A—renal system—kidney cancer	0.000205	0.0345	CbGeAlD
Sirolimus—MTOR—gonad—kidney cancer	0.000205	0.0344	CbGeAlD
Sirolimus—CYP3A7-CYP3A51P—cortex of kidney—kidney cancer	0.000203	0.0341	CbGeAlD
Sirolimus—FKBP1A—kidney—kidney cancer	0.000198	0.0333	CbGeAlD
Sirolimus—SLC47A1—nephron tubule—kidney cancer	0.000194	0.0326	CbGeAlD
Sirolimus—FKBP1A—cortex of kidney—kidney cancer	0.000193	0.0325	CbGeAlD
Sirolimus—Temsirolimus—MTOR—kidney cancer	0.000188	0.194	CrCbGaD
Sirolimus—FKBP1A—gonad—kidney cancer	0.000184	0.0309	CbGeAlD
Sirolimus—FKBP1A—cardiac atrium—kidney cancer	0.000184	0.0309	CbGeAlD
Sirolimus—SLC47A1—renal system—kidney cancer	0.000176	0.0296	CbGeAlD
Sirolimus—SLCO1B1—renal system—kidney cancer	0.000174	0.0293	CbGeAlD
Sirolimus—CYP3A4—Sunitinib—kidney cancer	0.000174	0.00109	CbGbCtD
Sirolimus—SLC47A1—kidney—kidney cancer	0.00017	0.0286	CbGeAlD
Sirolimus—SLCO1B1—kidney—kidney cancer	0.000168	0.0283	CbGeAlD
Sirolimus—SLC47A1—cortex of kidney—kidney cancer	0.000166	0.0279	CbGeAlD
Sirolimus—Tacrolimus—MTOR—kidney cancer	0.000166	0.171	CrCbGaD
Sirolimus—SLC47A1—gonad—kidney cancer	0.000158	0.0266	CbGeAlD
Sirolimus—CYP3A4—Doxorubicin—kidney cancer	0.00013	0.000819	CbGbCtD
Sirolimus—CYP3A5—nephron tubule—kidney cancer	9.83e-05	0.0165	CbGeAlD
Sirolimus—CYP3A5—renal system—kidney cancer	8.93e-05	0.015	CbGeAlD
Sirolimus—CYP3A5—kidney—kidney cancer	8.64e-05	0.0145	CbGeAlD
Sirolimus—CYP3A5—cortex of kidney—kidney cancer	8.41e-05	0.0141	CbGeAlD
Sirolimus—CYP3A4—renal system—kidney cancer	6.71e-05	0.0113	CbGeAlD
Sirolimus—CYP3A4—kidney—kidney cancer	6.48e-05	0.0109	CbGeAlD
Sirolimus—ABCB1—nephron tubule—kidney cancer	5.22e-05	0.00877	CbGeAlD
Sirolimus—ABCB1—renal system—kidney cancer	4.75e-05	0.00798	CbGeAlD
Sirolimus—ABCB1—kidney—kidney cancer	4.59e-05	0.00771	CbGeAlD
Sirolimus—ABCB1—cortex of kidney—kidney cancer	4.47e-05	0.00751	CbGeAlD
Sirolimus—ABCB1—gonad—kidney cancer	4.26e-05	0.00715	CbGeAlD
Sirolimus—Temsirolimus—ABCB1—kidney cancer	3.23e-05	0.0333	CrCbGaD
Sirolimus—Tacrolimus—ABCB1—kidney cancer	2.85e-05	0.0293	CrCbGaD
Sirolimus—Face oedema—Doxorubicin—kidney cancer	7.51e-06	0.000192	CcSEcCtD
Sirolimus—Decreased appetite—Gemcitabine—kidney cancer	7.51e-06	0.000192	CcSEcCtD
Sirolimus—Hypersensitivity—Dactinomycin—kidney cancer	7.51e-06	0.000192	CcSEcCtD
Sirolimus—Chills—Capecitabine—kidney cancer	7.49e-06	0.000191	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	7.49e-06	0.000191	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Gemcitabine—kidney cancer	7.46e-06	0.00019	CcSEcCtD
Sirolimus—Discomfort—Paclitaxel—kidney cancer	7.45e-06	0.00019	CcSEcCtD
Sirolimus—Gastrointestinal pain—Vincristine—kidney cancer	7.44e-06	0.00019	CcSEcCtD
Sirolimus—Dizziness—Sorafenib—kidney cancer	7.4e-06	0.000189	CcSEcCtD
Sirolimus—Pain—Gemcitabine—kidney cancer	7.39e-06	0.000188	CcSEcCtD
Sirolimus—Constipation—Gemcitabine—kidney cancer	7.39e-06	0.000188	CcSEcCtD
Sirolimus—Nausea—Erlotinib—kidney cancer	7.39e-06	0.000188	CcSEcCtD
Sirolimus—Mood swings—Doxorubicin—kidney cancer	7.37e-06	0.000188	CcSEcCtD
Sirolimus—Diarrhoea—Sunitinib—kidney cancer	7.36e-06	0.000188	CcSEcCtD
Sirolimus—Asthenia—Dactinomycin—kidney cancer	7.31e-06	0.000186	CcSEcCtD
Sirolimus—Confusional state—Paclitaxel—kidney cancer	7.29e-06	0.000186	CcSEcCtD
Sirolimus—Blood creatinine increased—Doxorubicin—kidney cancer	7.29e-06	0.000186	CcSEcCtD
Sirolimus—Malnutrition—Capecitabine—kidney cancer	7.27e-06	0.000185	CcSEcCtD
Sirolimus—Dehydration—Doxorubicin—kidney cancer	7.24e-06	0.000185	CcSEcCtD
Sirolimus—Anaphylactic shock—Paclitaxel—kidney cancer	7.23e-06	0.000184	CcSEcCtD
Sirolimus—Oedema—Paclitaxel—kidney cancer	7.23e-06	0.000184	CcSEcCtD
Sirolimus—Abdominal pain—Vincristine—kidney cancer	7.2e-06	0.000184	CcSEcCtD
Sirolimus—Body temperature increased—Vincristine—kidney cancer	7.2e-06	0.000184	CcSEcCtD
Sirolimus—Liver function test abnormal—Doxorubicin—kidney cancer	7.18e-06	0.000183	CcSEcCtD
Sirolimus—Infection—Paclitaxel—kidney cancer	7.18e-06	0.000183	CcSEcCtD
Sirolimus—Flatulence—Capecitabine—kidney cancer	7.16e-06	0.000183	CcSEcCtD
Sirolimus—Dizziness—Sunitinib—kidney cancer	7.12e-06	0.000182	CcSEcCtD
Sirolimus—Feeling abnormal—Gemcitabine—kidney cancer	7.12e-06	0.000182	CcSEcCtD
Sirolimus—Shock—Paclitaxel—kidney cancer	7.11e-06	0.000181	CcSEcCtD
Sirolimus—Vomiting—Sorafenib—kidney cancer	7.11e-06	0.000181	CcSEcCtD
Sirolimus—Orthostatic hypotension—Doxorubicin—kidney cancer	7.11e-06	0.000181	CcSEcCtD
Sirolimus—Nervous system disorder—Paclitaxel—kidney cancer	7.09e-06	0.000181	CcSEcCtD
Sirolimus—Hypokalaemia—Doxorubicin—kidney cancer	7.08e-06	0.000181	CcSEcCtD
Sirolimus—Thrombocytopenia—Paclitaxel—kidney cancer	7.08e-06	0.000181	CcSEcCtD
Sirolimus—Tachycardia—Paclitaxel—kidney cancer	7.06e-06	0.00018	CcSEcCtD
Sirolimus—Rash—Sorafenib—kidney cancer	7.05e-06	0.00018	CcSEcCtD
Sirolimus—Dermatitis—Sorafenib—kidney cancer	7.05e-06	0.00018	CcSEcCtD
Sirolimus—Back pain—Capecitabine—kidney cancer	7.03e-06	0.000179	CcSEcCtD
Sirolimus—Breast disorder—Doxorubicin—kidney cancer	7.03e-06	0.000179	CcSEcCtD
Sirolimus—Skin disorder—Paclitaxel—kidney cancer	7.02e-06	0.000179	CcSEcCtD
Sirolimus—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	7.01e-06	0.000179	CcSEcCtD
Sirolimus—Headache—Sorafenib—kidney cancer	7.01e-06	0.000179	CcSEcCtD
Sirolimus—Muscle spasms—Capecitabine—kidney cancer	6.99e-06	0.000178	CcSEcCtD
Sirolimus—Hyperhidrosis—Paclitaxel—kidney cancer	6.99e-06	0.000178	CcSEcCtD
Sirolimus—Diarrhoea—Dactinomycin—kidney cancer	6.97e-06	0.000178	CcSEcCtD
Sirolimus—Anorexia—Paclitaxel—kidney cancer	6.89e-06	0.000176	CcSEcCtD
Sirolimus—Gastritis—Doxorubicin—kidney cancer	6.89e-06	0.000176	CcSEcCtD
Sirolimus—Alanine aminotransferase increased—Doxorubicin—kidney cancer	6.86e-06	0.000175	CcSEcCtD
Sirolimus—Vomiting—Sunitinib—kidney cancer	6.84e-06	0.000175	CcSEcCtD
Sirolimus—Body temperature increased—Gemcitabine—kidney cancer	6.83e-06	0.000174	CcSEcCtD
Sirolimus—Tremor—Capecitabine—kidney cancer	6.81e-06	0.000174	CcSEcCtD
Sirolimus—Rash—Sunitinib—kidney cancer	6.79e-06	0.000173	CcSEcCtD
Sirolimus—Dermatitis—Sunitinib—kidney cancer	6.78e-06	0.000173	CcSEcCtD
Sirolimus—Abdominal distension—Doxorubicin—kidney cancer	6.77e-06	0.000173	CcSEcCtD
Sirolimus—Hypotension—Paclitaxel—kidney cancer	6.76e-06	0.000172	CcSEcCtD
Sirolimus—Ill-defined disorder—Capecitabine—kidney cancer	6.75e-06	0.000172	CcSEcCtD
Sirolimus—Headache—Sunitinib—kidney cancer	6.74e-06	0.000172	CcSEcCtD
Sirolimus—Influenza—Doxorubicin—kidney cancer	6.73e-06	0.000172	CcSEcCtD
Sirolimus—Asthma—Doxorubicin—kidney cancer	6.73e-06	0.000172	CcSEcCtD
Sirolimus—Dysphagia—Doxorubicin—kidney cancer	6.73e-06	0.000172	CcSEcCtD
Sirolimus—Anaemia—Capecitabine—kidney cancer	6.72e-06	0.000171	CcSEcCtD
Sirolimus—Hypersensitivity—Vincristine—kidney cancer	6.71e-06	0.000171	CcSEcCtD
Sirolimus—Nausea—Sorafenib—kidney cancer	6.64e-06	0.000169	CcSEcCtD
Sirolimus—Pancreatitis—Doxorubicin—kidney cancer	6.59e-06	0.000168	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Paclitaxel—kidney cancer	6.59e-06	0.000168	CcSEcCtD
Sirolimus—Malaise—Capecitabine—kidney cancer	6.56e-06	0.000167	CcSEcCtD
Sirolimus—Insomnia—Paclitaxel—kidney cancer	6.54e-06	0.000167	CcSEcCtD
Sirolimus—Asthenia—Vincristine—kidney cancer	6.53e-06	0.000167	CcSEcCtD
Sirolimus—Syncope—Capecitabine—kidney cancer	6.52e-06	0.000166	CcSEcCtD
Sirolimus—Leukopenia—Capecitabine—kidney cancer	6.51e-06	0.000166	CcSEcCtD
Sirolimus—Paraesthesia—Paclitaxel—kidney cancer	6.49e-06	0.000166	CcSEcCtD
Sirolimus—Vomiting—Dactinomycin—kidney cancer	6.48e-06	0.000165	CcSEcCtD
Sirolimus—Bronchitis—Doxorubicin—kidney cancer	6.47e-06	0.000165	CcSEcCtD
Sirolimus—Dyspnoea—Paclitaxel—kidney cancer	6.45e-06	0.000164	CcSEcCtD
Sirolimus—Somnolence—Paclitaxel—kidney cancer	6.43e-06	0.000164	CcSEcCtD
Sirolimus—Palpitations—Capecitabine—kidney cancer	6.43e-06	0.000164	CcSEcCtD
Sirolimus—Rash—Dactinomycin—kidney cancer	6.42e-06	0.000164	CcSEcCtD
Sirolimus—Nausea—Sunitinib—kidney cancer	6.39e-06	0.000163	CcSEcCtD
Sirolimus—Loss of consciousness—Capecitabine—kidney cancer	6.39e-06	0.000163	CcSEcCtD
Sirolimus—Pancytopenia—Doxorubicin—kidney cancer	6.39e-06	0.000163	CcSEcCtD
Sirolimus—Dyspepsia—Paclitaxel—kidney cancer	6.36e-06	0.000162	CcSEcCtD
Sirolimus—Cough—Capecitabine—kidney cancer	6.34e-06	0.000162	CcSEcCtD
Sirolimus—Neutropenia—Doxorubicin—kidney cancer	6.29e-06	0.00016	CcSEcCtD
Sirolimus—Dysuria—Doxorubicin—kidney cancer	6.29e-06	0.00016	CcSEcCtD
Sirolimus—Decreased appetite—Paclitaxel—kidney cancer	6.29e-06	0.00016	CcSEcCtD
Sirolimus—Hypertension—Capecitabine—kidney cancer	6.28e-06	0.00016	CcSEcCtD
Sirolimus—Upper respiratory tract infection—Doxorubicin—kidney cancer	6.25e-06	0.000159	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Paclitaxel—kidney cancer	6.24e-06	0.000159	CcSEcCtD
Sirolimus—Diarrhoea—Vincristine—kidney cancer	6.23e-06	0.000159	CcSEcCtD
Sirolimus—Pollakiuria—Doxorubicin—kidney cancer	6.21e-06	0.000159	CcSEcCtD
Sirolimus—Asthenia—Gemcitabine—kidney cancer	6.2e-06	0.000158	CcSEcCtD
Sirolimus—Myalgia—Capecitabine—kidney cancer	6.19e-06	0.000158	CcSEcCtD
Sirolimus—Arthralgia—Capecitabine—kidney cancer	6.19e-06	0.000158	CcSEcCtD
Sirolimus—Chest pain—Capecitabine—kidney cancer	6.19e-06	0.000158	CcSEcCtD
Sirolimus—Pain—Paclitaxel—kidney cancer	6.18e-06	0.000158	CcSEcCtD
Sirolimus—Constipation—Paclitaxel—kidney cancer	6.18e-06	0.000158	CcSEcCtD
Sirolimus—Anxiety—Capecitabine—kidney cancer	6.17e-06	0.000157	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	6.15e-06	0.000157	CcSEcCtD
Sirolimus—Weight increased—Doxorubicin—kidney cancer	6.12e-06	0.000156	CcSEcCtD
Sirolimus—Discomfort—Capecitabine—kidney cancer	6.12e-06	0.000156	CcSEcCtD
Sirolimus—Pruritus—Gemcitabine—kidney cancer	6.11e-06	0.000156	CcSEcCtD
Sirolimus—Weight decreased—Doxorubicin—kidney cancer	6.09e-06	0.000155	CcSEcCtD
Sirolimus—Hyperglycaemia—Doxorubicin—kidney cancer	6.07e-06	0.000155	CcSEcCtD
Sirolimus—Nausea—Dactinomycin—kidney cancer	6.05e-06	0.000154	CcSEcCtD
Sirolimus—Pneumonia—Doxorubicin—kidney cancer	6.03e-06	0.000154	CcSEcCtD
Sirolimus—Dizziness—Vincristine—kidney cancer	6.02e-06	0.000154	CcSEcCtD
Sirolimus—Infestation NOS—Doxorubicin—kidney cancer	6e-06	0.000153	CcSEcCtD
Sirolimus—Infestation—Doxorubicin—kidney cancer	6e-06	0.000153	CcSEcCtD
Sirolimus—Confusional state—Capecitabine—kidney cancer	5.98e-06	0.000153	CcSEcCtD
Sirolimus—Feeling abnormal—Paclitaxel—kidney cancer	5.96e-06	0.000152	CcSEcCtD
Sirolimus—Oedema—Capecitabine—kidney cancer	5.93e-06	0.000151	CcSEcCtD
Sirolimus—Gastrointestinal pain—Paclitaxel—kidney cancer	5.91e-06	0.000151	CcSEcCtD
Sirolimus—Diarrhoea—Gemcitabine—kidney cancer	5.91e-06	0.000151	CcSEcCtD
Sirolimus—Infection—Capecitabine—kidney cancer	5.89e-06	0.00015	CcSEcCtD
Sirolimus—Neuropathy peripheral—Doxorubicin—kidney cancer	5.88e-06	0.00015	CcSEcCtD
Sirolimus—Stomatitis—Doxorubicin—kidney cancer	5.85e-06	0.000149	CcSEcCtD
Sirolimus—Shock—Capecitabine—kidney cancer	5.84e-06	0.000149	CcSEcCtD
Sirolimus—Conjunctivitis—Doxorubicin—kidney cancer	5.83e-06	0.000149	CcSEcCtD
Sirolimus—Urinary tract infection—Doxorubicin—kidney cancer	5.83e-06	0.000149	CcSEcCtD
Sirolimus—Nervous system disorder—Capecitabine—kidney cancer	5.82e-06	0.000148	CcSEcCtD
Sirolimus—Thrombocytopenia—Capecitabine—kidney cancer	5.81e-06	0.000148	CcSEcCtD
Sirolimus—Tachycardia—Capecitabine—kidney cancer	5.79e-06	0.000148	CcSEcCtD
Sirolimus—Vomiting—Vincristine—kidney cancer	5.79e-06	0.000148	CcSEcCtD
Sirolimus—Skin disorder—Capecitabine—kidney cancer	5.76e-06	0.000147	CcSEcCtD
Sirolimus—Sweating—Doxorubicin—kidney cancer	5.75e-06	0.000147	CcSEcCtD
Sirolimus—Rash—Vincristine—kidney cancer	5.74e-06	0.000146	CcSEcCtD
Sirolimus—Hyperhidrosis—Capecitabine—kidney cancer	5.74e-06	0.000146	CcSEcCtD
Sirolimus—Dermatitis—Vincristine—kidney cancer	5.73e-06	0.000146	CcSEcCtD
Sirolimus—Haematuria—Doxorubicin—kidney cancer	5.72e-06	0.000146	CcSEcCtD
Sirolimus—Body temperature increased—Paclitaxel—kidney cancer	5.72e-06	0.000146	CcSEcCtD
Sirolimus—Abdominal pain—Paclitaxel—kidney cancer	5.72e-06	0.000146	CcSEcCtD
Sirolimus—Headache—Vincristine—kidney cancer	5.7e-06	0.000145	CcSEcCtD
Sirolimus—Hepatobiliary disease—Doxorubicin—kidney cancer	5.67e-06	0.000145	CcSEcCtD
Sirolimus—Epistaxis—Doxorubicin—kidney cancer	5.66e-06	0.000144	CcSEcCtD
Sirolimus—Anorexia—Capecitabine—kidney cancer	5.66e-06	0.000144	CcSEcCtD
Sirolimus—Sinusitis—Doxorubicin—kidney cancer	5.63e-06	0.000144	CcSEcCtD
Sirolimus—Hypotension—Capecitabine—kidney cancer	5.54e-06	0.000141	CcSEcCtD
Sirolimus—Vomiting—Gemcitabine—kidney cancer	5.49e-06	0.00014	CcSEcCtD
Sirolimus—Rash—Gemcitabine—kidney cancer	5.45e-06	0.000139	CcSEcCtD
Sirolimus—Dermatitis—Gemcitabine—kidney cancer	5.44e-06	0.000139	CcSEcCtD
Sirolimus—Haemoglobin—Doxorubicin—kidney cancer	5.41e-06	0.000138	CcSEcCtD
Sirolimus—Headache—Gemcitabine—kidney cancer	5.41e-06	0.000138	CcSEcCtD
Sirolimus—Nausea—Vincristine—kidney cancer	5.41e-06	0.000138	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Capecitabine—kidney cancer	5.41e-06	0.000138	CcSEcCtD
Sirolimus—Rhinitis—Doxorubicin—kidney cancer	5.4e-06	0.000138	CcSEcCtD
Sirolimus—Haemorrhage—Doxorubicin—kidney cancer	5.38e-06	0.000137	CcSEcCtD
Sirolimus—Insomnia—Capecitabine—kidney cancer	5.37e-06	0.000137	CcSEcCtD
Sirolimus—Hypoaesthesia—Doxorubicin—kidney cancer	5.36e-06	0.000137	CcSEcCtD
Sirolimus—Pharyngitis—Doxorubicin—kidney cancer	5.34e-06	0.000136	CcSEcCtD
Sirolimus—Paraesthesia—Capecitabine—kidney cancer	5.33e-06	0.000136	CcSEcCtD
Sirolimus—Hypersensitivity—Paclitaxel—kidney cancer	5.33e-06	0.000136	CcSEcCtD
Sirolimus—Urinary tract disorder—Doxorubicin—kidney cancer	5.32e-06	0.000136	CcSEcCtD
Sirolimus—Oedema peripheral—Doxorubicin—kidney cancer	5.3e-06	0.000135	CcSEcCtD
Sirolimus—Connective tissue disorder—Doxorubicin—kidney cancer	5.29e-06	0.000135	CcSEcCtD
Sirolimus—Dyspnoea—Capecitabine—kidney cancer	5.29e-06	0.000135	CcSEcCtD
Sirolimus—Urethral disorder—Doxorubicin—kidney cancer	5.28e-06	0.000135	CcSEcCtD
Sirolimus—Dyspepsia—Capecitabine—kidney cancer	5.22e-06	0.000133	CcSEcCtD
Sirolimus—Visual impairment—Doxorubicin—kidney cancer	5.19e-06	0.000132	CcSEcCtD
Sirolimus—Asthenia—Paclitaxel—kidney cancer	5.19e-06	0.000132	CcSEcCtD
Sirolimus—Decreased appetite—Capecitabine—kidney cancer	5.16e-06	0.000132	CcSEcCtD
Sirolimus—Nausea—Gemcitabine—kidney cancer	5.13e-06	0.000131	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Capecitabine—kidney cancer	5.12e-06	0.000131	CcSEcCtD
Sirolimus—Pruritus—Paclitaxel—kidney cancer	5.12e-06	0.00013	CcSEcCtD
Sirolimus—Pain—Capecitabine—kidney cancer	5.07e-06	0.000129	CcSEcCtD
Sirolimus—Constipation—Capecitabine—kidney cancer	5.07e-06	0.000129	CcSEcCtD
Sirolimus—Tinnitus—Doxorubicin—kidney cancer	5.02e-06	0.000128	CcSEcCtD
Sirolimus—Cardiac disorder—Doxorubicin—kidney cancer	5e-06	0.000127	CcSEcCtD
Sirolimus—Diarrhoea—Paclitaxel—kidney cancer	4.95e-06	0.000126	CcSEcCtD
Sirolimus—Feeling abnormal—Capecitabine—kidney cancer	4.89e-06	0.000125	CcSEcCtD
Sirolimus—Angiopathy—Doxorubicin—kidney cancer	4.88e-06	0.000125	CcSEcCtD
Sirolimus—Immune system disorder—Doxorubicin—kidney cancer	4.86e-06	0.000124	CcSEcCtD
Sirolimus—Gastrointestinal pain—Capecitabine—kidney cancer	4.85e-06	0.000124	CcSEcCtD
Sirolimus—Mediastinal disorder—Doxorubicin—kidney cancer	4.85e-06	0.000124	CcSEcCtD
Sirolimus—Chills—Doxorubicin—kidney cancer	4.83e-06	0.000123	CcSEcCtD
Sirolimus—Dizziness—Paclitaxel—kidney cancer	4.78e-06	0.000122	CcSEcCtD
Sirolimus—Body temperature increased—Capecitabine—kidney cancer	4.69e-06	0.00012	CcSEcCtD
Sirolimus—Abdominal pain—Capecitabine—kidney cancer	4.69e-06	0.00012	CcSEcCtD
Sirolimus—Malnutrition—Doxorubicin—kidney cancer	4.69e-06	0.00012	CcSEcCtD
Sirolimus—Flatulence—Doxorubicin—kidney cancer	4.62e-06	0.000118	CcSEcCtD
Sirolimus—Tension—Doxorubicin—kidney cancer	4.6e-06	0.000117	CcSEcCtD
Sirolimus—Vomiting—Paclitaxel—kidney cancer	4.6e-06	0.000117	CcSEcCtD
Sirolimus—Rash—Paclitaxel—kidney cancer	4.56e-06	0.000116	CcSEcCtD
Sirolimus—Dermatitis—Paclitaxel—kidney cancer	4.55e-06	0.000116	CcSEcCtD
Sirolimus—Nervousness—Doxorubicin—kidney cancer	4.55e-06	0.000116	CcSEcCtD
Sirolimus—Back pain—Doxorubicin—kidney cancer	4.53e-06	0.000116	CcSEcCtD
Sirolimus—Headache—Paclitaxel—kidney cancer	4.53e-06	0.000116	CcSEcCtD
Sirolimus—Muscle spasms—Doxorubicin—kidney cancer	4.51e-06	0.000115	CcSEcCtD
Sirolimus—Hypersensitivity—Capecitabine—kidney cancer	4.37e-06	0.000112	CcSEcCtD
Sirolimus—Ill-defined disorder—Doxorubicin—kidney cancer	4.35e-06	0.000111	CcSEcCtD
Sirolimus—Anaemia—Doxorubicin—kidney cancer	4.33e-06	0.00011	CcSEcCtD
Sirolimus—Agitation—Doxorubicin—kidney cancer	4.31e-06	0.00011	CcSEcCtD
Sirolimus—Nausea—Paclitaxel—kidney cancer	4.29e-06	0.00011	CcSEcCtD
Sirolimus—Asthenia—Capecitabine—kidney cancer	4.26e-06	0.000109	CcSEcCtD
Sirolimus—Malaise—Doxorubicin—kidney cancer	4.23e-06	0.000108	CcSEcCtD
Sirolimus—Syncope—Doxorubicin—kidney cancer	4.2e-06	0.000107	CcSEcCtD
Sirolimus—Pruritus—Capecitabine—kidney cancer	4.2e-06	0.000107	CcSEcCtD
Sirolimus—Leukopenia—Doxorubicin—kidney cancer	4.2e-06	0.000107	CcSEcCtD
Sirolimus—Palpitations—Doxorubicin—kidney cancer	4.14e-06	0.000106	CcSEcCtD
Sirolimus—Loss of consciousness—Doxorubicin—kidney cancer	4.12e-06	0.000105	CcSEcCtD
Sirolimus—Cough—Doxorubicin—kidney cancer	4.09e-06	0.000104	CcSEcCtD
Sirolimus—Diarrhoea—Capecitabine—kidney cancer	4.06e-06	0.000104	CcSEcCtD
Sirolimus—Hypertension—Doxorubicin—kidney cancer	4.05e-06	0.000103	CcSEcCtD
Sirolimus—Arthralgia—Doxorubicin—kidney cancer	3.99e-06	0.000102	CcSEcCtD
Sirolimus—Chest pain—Doxorubicin—kidney cancer	3.99e-06	0.000102	CcSEcCtD
Sirolimus—Myalgia—Doxorubicin—kidney cancer	3.99e-06	0.000102	CcSEcCtD
Sirolimus—Anxiety—Doxorubicin—kidney cancer	3.98e-06	0.000101	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	3.96e-06	0.000101	CcSEcCtD
Sirolimus—Discomfort—Doxorubicin—kidney cancer	3.94e-06	0.000101	CcSEcCtD
Sirolimus—Dizziness—Capecitabine—kidney cancer	3.92e-06	0.0001	CcSEcCtD
Sirolimus—Confusional state—Doxorubicin—kidney cancer	3.86e-06	9.84e-05	CcSEcCtD
Sirolimus—Anaphylactic shock—Doxorubicin—kidney cancer	3.82e-06	9.76e-05	CcSEcCtD
Sirolimus—Oedema—Doxorubicin—kidney cancer	3.82e-06	9.76e-05	CcSEcCtD
Sirolimus—Infection—Doxorubicin—kidney cancer	3.8e-06	9.69e-05	CcSEcCtD
Sirolimus—Vomiting—Capecitabine—kidney cancer	3.77e-06	9.62e-05	CcSEcCtD
Sirolimus—Shock—Doxorubicin—kidney cancer	3.76e-06	9.6e-05	CcSEcCtD
Sirolimus—Nervous system disorder—Doxorubicin—kidney cancer	3.75e-06	9.57e-05	CcSEcCtD
Sirolimus—Thrombocytopenia—Doxorubicin—kidney cancer	3.74e-06	9.55e-05	CcSEcCtD
Sirolimus—Rash—Capecitabine—kidney cancer	3.74e-06	9.54e-05	CcSEcCtD
Sirolimus—Dermatitis—Capecitabine—kidney cancer	3.74e-06	9.54e-05	CcSEcCtD
Sirolimus—Tachycardia—Doxorubicin—kidney cancer	3.73e-06	9.52e-05	CcSEcCtD
Sirolimus—Headache—Capecitabine—kidney cancer	3.72e-06	9.48e-05	CcSEcCtD
Sirolimus—Skin disorder—Doxorubicin—kidney cancer	3.72e-06	9.48e-05	CcSEcCtD
Sirolimus—Hyperhidrosis—Doxorubicin—kidney cancer	3.7e-06	9.43e-05	CcSEcCtD
Sirolimus—Anorexia—Doxorubicin—kidney cancer	3.65e-06	9.3e-05	CcSEcCtD
Sirolimus—Hypotension—Doxorubicin—kidney cancer	3.57e-06	9.12e-05	CcSEcCtD
Sirolimus—Nausea—Capecitabine—kidney cancer	3.52e-06	8.99e-05	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Doxorubicin—kidney cancer	3.48e-06	8.89e-05	CcSEcCtD
Sirolimus—Insomnia—Doxorubicin—kidney cancer	3.46e-06	8.82e-05	CcSEcCtD
Sirolimus—Paraesthesia—Doxorubicin—kidney cancer	3.43e-06	8.76e-05	CcSEcCtD
Sirolimus—Dyspnoea—Doxorubicin—kidney cancer	3.41e-06	8.7e-05	CcSEcCtD
Sirolimus—Somnolence—Doxorubicin—kidney cancer	3.4e-06	8.67e-05	CcSEcCtD
Sirolimus—Dyspepsia—Doxorubicin—kidney cancer	3.37e-06	8.59e-05	CcSEcCtD
Sirolimus—Decreased appetite—Doxorubicin—kidney cancer	3.32e-06	8.48e-05	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Doxorubicin—kidney cancer	3.3e-06	8.42e-05	CcSEcCtD
Sirolimus—Pain—Doxorubicin—kidney cancer	3.27e-06	8.34e-05	CcSEcCtD
Sirolimus—Constipation—Doxorubicin—kidney cancer	3.27e-06	8.34e-05	CcSEcCtD
Sirolimus—Feeling abnormal—Doxorubicin—kidney cancer	3.15e-06	8.04e-05	CcSEcCtD
Sirolimus—Gastrointestinal pain—Doxorubicin—kidney cancer	3.13e-06	7.98e-05	CcSEcCtD
Sirolimus—Abdominal pain—Doxorubicin—kidney cancer	3.02e-06	7.71e-05	CcSEcCtD
Sirolimus—Body temperature increased—Doxorubicin—kidney cancer	3.02e-06	7.71e-05	CcSEcCtD
Sirolimus—Hypersensitivity—Doxorubicin—kidney cancer	2.82e-06	7.19e-05	CcSEcCtD
Sirolimus—Asthenia—Doxorubicin—kidney cancer	2.74e-06	7e-05	CcSEcCtD
Sirolimus—Pruritus—Doxorubicin—kidney cancer	2.71e-06	6.9e-05	CcSEcCtD
Sirolimus—Diarrhoea—Doxorubicin—kidney cancer	2.62e-06	6.68e-05	CcSEcCtD
Sirolimus—Dizziness—Doxorubicin—kidney cancer	2.53e-06	6.45e-05	CcSEcCtD
Sirolimus—Vomiting—Doxorubicin—kidney cancer	2.43e-06	6.2e-05	CcSEcCtD
Sirolimus—Rash—Doxorubicin—kidney cancer	2.41e-06	6.15e-05	CcSEcCtD
Sirolimus—Dermatitis—Doxorubicin—kidney cancer	2.41e-06	6.15e-05	CcSEcCtD
Sirolimus—Headache—Doxorubicin—kidney cancer	2.4e-06	6.11e-05	CcSEcCtD
Sirolimus—Nausea—Doxorubicin—kidney cancer	2.27e-06	5.8e-05	CcSEcCtD
Sirolimus—EIF4E—Signaling Pathways—IL2—kidney cancer	1.35e-06	5.71e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CRABP1—kidney cancer	1.35e-06	5.7e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—POMC—kidney cancer	1.34e-06	5.67e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—PTEN—kidney cancer	1.34e-06	5.66e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—PTEN—kidney cancer	1.33e-06	5.63e-05	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—PIK3CA—kidney cancer	1.33e-06	5.6e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—BRAF—kidney cancer	1.33e-06	5.6e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CCBL1—kidney cancer	1.32e-06	5.58e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CCND1—kidney cancer	1.32e-06	5.57e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—JUN—kidney cancer	1.32e-06	5.56e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—SLC2A1—kidney cancer	1.32e-06	5.56e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—kidney cancer	1.31e-06	5.55e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CTNNB1—kidney cancer	1.31e-06	5.52e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—RAF1—kidney cancer	1.3e-06	5.48e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—RELA—kidney cancer	1.29e-06	5.46e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—HIF1A—kidney cancer	1.29e-06	5.43e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—ERBB2—kidney cancer	1.28e-06	5.42e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—TSC2—kidney cancer	1.28e-06	5.42e-05	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—PIK3CA—kidney cancer	1.27e-06	5.38e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—PTEN—kidney cancer	1.27e-06	5.38e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—MTOR—kidney cancer	1.27e-06	5.35e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CD4—kidney cancer	1.26e-06	5.34e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ITPR2—kidney cancer	1.25e-06	5.3e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—kidney cancer	1.24e-06	5.25e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—KIT—kidney cancer	1.23e-06	5.18e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—HIF1A—kidney cancer	1.21e-06	5.12e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.21e-06	5.12e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TSC2—kidney cancer	1.21e-06	5.11e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—kidney cancer	1.21e-06	5.1e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—RAF1—kidney cancer	1.2e-06	5.06e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CA9—kidney cancer	1.2e-06	5.06e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—GSTP1—kidney cancer	1.2e-06	5.05e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—MAPK3—kidney cancer	1.19e-06	5.03e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CDKN1B—kidney cancer	1.19e-06	5.02e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—ERBB2—kidney cancer	1.18e-06	5.01e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—kidney cancer	1.18e-06	4.99e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—MTOR—kidney cancer	1.17e-06	4.94e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—CD4—kidney cancer	1.17e-06	4.93e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL2—kidney cancer	1.16e-06	4.91e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—KDR—kidney cancer	1.16e-06	4.9e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—PTGS2—kidney cancer	1.16e-06	4.89e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—VEGFA—kidney cancer	1.15e-06	4.86e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PPAT—kidney cancer	1.14e-06	4.84e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GLIPR1—kidney cancer	1.14e-06	4.84e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GSTT1—kidney cancer	1.14e-06	4.83e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ACHE—kidney cancer	1.14e-06	4.83e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—MAPK3—kidney cancer	1.14e-06	4.81e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—MAPK1—kidney cancer	1.13e-06	4.79e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—APC—kidney cancer	1.13e-06	4.78e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—KIT—kidney cancer	1.13e-06	4.78e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—JUN—kidney cancer	1.13e-06	4.78e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ABCB1—kidney cancer	1.13e-06	4.78e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IGF2—kidney cancer	1.13e-06	4.78e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CDH1—kidney cancer	1.13e-06	4.77e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CDKN2B—kidney cancer	1.13e-06	4.76e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CTNNB1—kidney cancer	1.12e-06	4.74e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—kidney cancer	1.12e-06	4.72e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—MYC—kidney cancer	1.11e-06	4.68e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—RAF1—kidney cancer	1.11e-06	4.68e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—RELA—kidney cancer	1.1e-06	4.65e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—GSTM1—kidney cancer	1.1e-06	4.64e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—CDKN1B—kidney cancer	1.1e-06	4.64e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GSTP1—kidney cancer	1.1e-06	4.63e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—ERBB2—kidney cancer	1.09e-06	4.63e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—PTEN—kidney cancer	1.09e-06	4.62e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IGF1R—kidney cancer	1.09e-06	4.62e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MAPK3—kidney cancer	1.09e-06	4.59e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—MAPK1—kidney cancer	1.08e-06	4.58e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—SCARB1—kidney cancer	1.08e-06	4.57e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MTOR—kidney cancer	1.08e-06	4.56e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PTGS1—kidney cancer	1.07e-06	4.53e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—KRAS—kidney cancer	1.07e-06	4.52e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—APC—kidney cancer	1.07e-06	4.51e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—KIT—kidney cancer	1.07e-06	4.51e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—BRAF—kidney cancer	1.06e-06	4.5e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—FH—kidney cancer	1.06e-06	4.5e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—APRT—kidney cancer	1.06e-06	4.5e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MYC—kidney cancer	1.06e-06	4.47e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PSMD7—kidney cancer	1.05e-06	4.44e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CYP1A1—kidney cancer	1.04e-06	4.4e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ABCB1—kidney cancer	1.04e-06	4.39e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—CTNNB1—kidney cancer	1.04e-06	4.38e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MAPK1—kidney cancer	1.03e-06	4.37e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—KRAS—kidney cancer	1.03e-06	4.34e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	1.03e-06	4.33e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—KRAS—kidney cancer	1.02e-06	4.32e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CRABP1—kidney cancer	1.02e-06	4.3e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—POMC—kidney cancer	1.02e-06	4.3e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CDKN1B—kidney cancer	1.01e-06	4.28e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—PTEN—kidney cancer	1.01e-06	4.27e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GSTM1—kidney cancer	1.01e-06	4.26e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—BRAF—kidney cancer	1e-06	4.24e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GPC3—kidney cancer	1e-06	4.23e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—BCHE—kidney cancer	9.97e-07	4.21e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IL2—kidney cancer	9.92e-07	4.19e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	9.92e-07	4.19e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—SLC5A5—kidney cancer	9.84e-07	4.16e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—PIK3CA—kidney cancer	9.84e-07	4.16e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—KRAS—kidney cancer	9.77e-07	4.13e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CA2—kidney cancer	9.74e-07	4.11e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CCND1—kidney cancer	9.67e-07	4.09e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—JUN—kidney cancer	9.65e-07	4.08e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—RAF1—kidney cancer	9.63e-07	4.07e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—RELA—kidney cancer	9.58e-07	4.05e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CTNNB1—kidney cancer	9.58e-07	4.05e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CYP1A1—kidney cancer	9.56e-07	4.04e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—ERBB2—kidney cancer	9.52e-07	4.02e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—SLC2A1—kidney cancer	9.51e-07	4.02e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ALAD—kidney cancer	9.49e-07	4.01e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ITPR2—kidney cancer	9.47e-07	4e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—PIK3CA—kidney cancer	9.45e-07	3.99e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—PIK3CA—kidney cancer	9.41e-07	3.97e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CD4—kidney cancer	9.38e-07	3.96e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—MAPK3—kidney cancer	9.35e-07	3.95e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PTEN—kidney cancer	9.34e-07	3.94e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ST3GAL2—kidney cancer	9.26e-07	3.91e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ALDH1A1—kidney cancer	9.05e-07	3.82e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HIF1A—kidney cancer	9e-07	3.8e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—PIK3CA—kidney cancer	8.98e-07	3.79e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TSC2—kidney cancer	8.98e-07	3.79e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—MAPK1—kidney cancer	8.9e-07	3.76e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—RAF1—kidney cancer	8.89e-07	3.75e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CDKN1B—kidney cancer	8.82e-07	3.73e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—ERBB2—kidney cancer	8.79e-07	3.71e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TP53—kidney cancer	8.69e-07	3.67e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SLC5A3—kidney cancer	8.68e-07	3.67e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PGK1—kidney cancer	8.68e-07	3.67e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—CD4—kidney cancer	8.66e-07	3.66e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—MAPK3—kidney cancer	8.63e-07	3.65e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GSTT1—kidney cancer	8.63e-07	3.65e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ACHE—kidney cancer	8.63e-07	3.65e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL2—kidney cancer	8.63e-07	3.65e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KDR—kidney cancer	8.61e-07	3.64e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PTGS2—kidney cancer	8.6e-07	3.63e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	8.55e-07	3.61e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—LDHB—kidney cancer	8.51e-07	3.59e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—VEGFA—kidney cancer	8.43e-07	3.56e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—KRAS—kidney cancer	8.4e-07	3.55e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—MYC—kidney cancer	8.4e-07	3.55e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—JUN—kidney cancer	8.4e-07	3.55e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—RAF1—kidney cancer	8.39e-07	3.54e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—RELA—kidney cancer	8.35e-07	3.53e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CTNNB1—kidney cancer	8.33e-07	3.52e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—ERBB2—kidney cancer	8.3e-07	3.51e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—MAPK1—kidney cancer	8.21e-07	3.47e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MTOR—kidney cancer	8.19e-07	3.46e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—SCARB1—kidney cancer	8.17e-07	3.45e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—CDKN1B—kidney cancer	8.14e-07	3.44e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PTEN—kidney cancer	8.12e-07	3.43e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PTGS1—kidney cancer	8.09e-07	3.42e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MAPK3—kidney cancer	7.98e-07	3.37e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PSMD7—kidney cancer	7.93e-07	3.35e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KIT—kidney cancer	7.93e-07	3.35e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—APC—kidney cancer	7.93e-07	3.35e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GSTP1—kidney cancer	7.93e-07	3.35e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—POMC—kidney cancer	7.76e-07	3.28e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MYC—kidney cancer	7.76e-07	3.28e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—KRAS—kidney cancer	7.76e-07	3.28e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—PIK3CA—kidney cancer	7.72e-07	3.26e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—CTNNB1—kidney cancer	7.69e-07	3.25e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CDKN1B—kidney cancer	7.68e-07	3.25e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MAPK1—kidney cancer	7.59e-07	3.21e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—POMC—kidney cancer	7.55e-07	3.19e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—BCHE—kidney cancer	7.52e-07	3.18e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IL2—kidney cancer	7.52e-07	3.18e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ABCB1—kidney cancer	7.51e-07	3.17e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PTEN—kidney cancer	7.5e-07	3.17e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—BRAF—kidney cancer	7.45e-07	3.15e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—SLC5A5—kidney cancer	7.43e-07	3.14e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CA9—kidney cancer	7.38e-07	3.12e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCND1—kidney cancer	7.33e-07	3.1e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—JUN—kidney cancer	7.32e-07	3.09e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GSTM1—kidney cancer	7.29e-07	3.08e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CTNNB1—kidney cancer	7.26e-07	3.07e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—SLC2A1—kidney cancer	7.17e-07	3.03e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—KRAS—kidney cancer	7.17e-07	3.03e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—PIK3CA—kidney cancer	7.13e-07	3.01e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—POMC—kidney cancer	7.12e-07	3.01e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PTEN—kidney cancer	7.08e-07	2.99e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—MAPK3—kidney cancer	6.94e-07	2.93e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CYP1A1—kidney cancer	6.91e-07	2.92e-05	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—RAF1—kidney cancer	6.84e-07	2.89e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—MAPK1—kidney cancer	6.6e-07	2.79e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PIK3CA—kidney cancer	6.59e-07	2.78e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—MAPK3—kidney cancer	6.41e-07	2.71e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—VEGFA—kidney cancer	6.39e-07	2.7e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TP53—kidney cancer	6.37e-07	2.69e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CRABP1—kidney cancer	6.27e-07	2.65e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—KRAS—kidney cancer	6.24e-07	2.63e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—MYC—kidney cancer	6.23e-07	2.63e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—RAF1—kidney cancer	6.22e-07	2.63e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—RELA—kidney cancer	6.2e-07	2.62e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PTGS2—kidney cancer	6.19e-07	2.62e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ERBB2—kidney cancer	6.16e-07	2.6e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—MAPK1—kidney cancer	6.1e-07	2.58e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MAPK3—kidney cancer	6.05e-07	2.55e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GSTP1—kidney cancer	5.98e-07	2.53e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MYC—kidney cancer	5.88e-07	2.48e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ITPR2—kidney cancer	5.83e-07	2.46e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—KRAS—kidney cancer	5.76e-07	2.43e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MAPK1—kidney cancer	5.75e-07	2.43e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PIK3CA—kidney cancer	5.73e-07	2.42e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CDKN1B—kidney cancer	5.7e-07	2.41e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PTGS2—kidney cancer	5.68e-07	2.4e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL2—kidney cancer	5.58e-07	2.36e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GSTM1—kidney cancer	5.5e-07	2.32e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCND1—kidney cancer	5.44e-07	2.3e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—KRAS—kidney cancer	5.43e-07	2.3e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—JUN—kidney cancer	5.43e-07	2.29e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PTEN—kidney cancer	5.4e-07	2.28e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CTNNB1—kidney cancer	5.39e-07	2.28e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTT1—kidney cancer	5.32e-07	2.25e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ACHE—kidney cancer	5.32e-07	2.25e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PIK3CA—kidney cancer	5.29e-07	2.23e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PTEN—kidney cancer	5.25e-07	2.22e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP1A1—kidney cancer	5.21e-07	2.2e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—POMC—kidney cancer	5.15e-07	2.18e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SCARB1—kidney cancer	5.03e-07	2.13e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PIK3CA—kidney cancer	4.99e-07	2.11e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PTGS1—kidney cancer	4.98e-07	2.11e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PTEN—kidney cancer	4.96e-07	2.09e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PSMD7—kidney cancer	4.89e-07	2.06e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TP53—kidney cancer	4.83e-07	2.04e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—VEGFA—kidney cancer	4.74e-07	2e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—BCHE—kidney cancer	4.63e-07	1.96e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SLC5A5—kidney cancer	4.58e-07	1.93e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MAPK3—kidney cancer	4.49e-07	1.9e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SLC2A1—kidney cancer	4.42e-07	1.87e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MYC—kidney cancer	4.36e-07	1.84e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MAPK1—kidney cancer	4.27e-07	1.8e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PTGS2—kidney cancer	4.11e-07	1.74e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KRAS—kidney cancer	4.03e-07	1.7e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—POMC—kidney cancer	3.89e-07	1.64e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PIK3CA—kidney cancer	3.81e-07	1.61e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PIK3CA—kidney cancer	3.7e-07	1.56e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTP1—kidney cancer	3.69e-07	1.56e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TP53—kidney cancer	3.58e-07	1.51e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PTEN—kidney cancer	3.58e-07	1.51e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PIK3CA—kidney cancer	3.5e-07	1.48e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ABCB1—kidney cancer	3.49e-07	1.47e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTM1—kidney cancer	3.39e-07	1.43e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYP1A1—kidney cancer	3.21e-07	1.36e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PTGS2—kidney cancer	3.1e-07	1.31e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PTEN—kidney cancer	2.7e-07	1.14e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PIK3CA—kidney cancer	2.53e-07	1.07e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—POMC—kidney cancer	2.39e-07	1.01e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PTGS2—kidney cancer	1.91e-07	8.07e-06	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PIK3CA—kidney cancer	1.91e-07	8.06e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PTEN—kidney cancer	1.67e-07	7.04e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PIK3CA—kidney cancer	1.17e-07	4.96e-06	CbGpPWpGaD
